Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $53.67 Average Price Target from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has been given a consensus rating of “Moderate Buy” by the ten analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $53.6667.

CAPR has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, May 13th. Roth Capital reissued a “buy” rating and issued a $38.00 price target on shares of Capricor Therapeutics in a report on Friday, May 15th. Finally, LADENBURG THALM/SH SH upgraded Capricor Therapeutics to a “strong-buy” rating in a research report on Thursday, June 25th.

Capricor Therapeutics Price Performance

Shares of NASDAQ:CAPR opened at $19.70 on Friday. Capricor Therapeutics has a 52-week low of $4.30 and a 52-week high of $40.37. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -8.49 and a beta of 0.42. The business has a 50-day moving average price of $25.29 and a 200-day moving average price of $27.48.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, equities analysts anticipate that Capricor Therapeutics will post -0.49 EPS for the current fiscal year.

Insider Activity

In other news, CFO Anthony Bergmann sold 24,100 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the sale, the chief financial officer directly owned 11,223 shares in the company, valued at $340,954.74. This trade represents a 68.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 50,000 shares of company stock worth $1,551,658. Corporate insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Capricor Therapeutics by 16.1% in the fourth quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock worth $73,936,000 after buying an additional 355,161 shares in the last quarter. Suvretta Capital Management LLC purchased a new stake in Capricor Therapeutics during the 4th quarter valued at about $51,533,000. Tang Capital Management LLC acquired a new stake in Capricor Therapeutics in the 4th quarter valued at about $49,062,000. RA Capital Management L.P. acquired a new stake in Capricor Therapeutics in the 4th quarter valued at about $43,516,000. Finally, Geode Capital Management LLC lifted its stake in Capricor Therapeutics by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock worth $29,367,000 after purchasing an additional 55,766 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.